证券代码：603590 证券简称：康辰药业 公告编号：临 2025-051 北京康辰药业股份有限公司 股东减持股份计划公告 刘建华先生在公司《首次公开发行股票招股说明书》中承诺如下： 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 大股东持股的基本情况 本次减持计划实施前，北京康辰药业股份有限公司（以下简称"公司"）控 股股东刘建华先生持有公司股份 50,786,760 股，占公司总股本的 31.87%（以公 司截至 2025 年 9 月 5 日总股本即 159,356,477 股为基数计算，下同）。 ? 减持计划的主要内容 自本公告披露之日起 15 个交易日后的 3 个月内（根据法律法规禁止减持的 期间除外），刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式减持其 所持有的公司股份，合计不超过 4,780,693 股，即不超过规定的公司股份总数的 超过公司股份总数的 1%；采取大宗交易方式的，在任意连续 90 日内，减持股份 的总数不超过公司股份总数的 2%。减持价格按照减持实施时的市场价格 ...

智通财经APP讯，康辰药业(603590.SH)发布公告，自公告披露之日起15个交易日后的3个月内(根据法律 法规禁止减持的期间除外)，公司控股股东刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式 减持其所持有的公司股份，合计不超过478.07万股，即不超过规定的公司股份总数的3%。 （原标题：康辰药业(603590.SH)控股股东拟减持不超3%股份） ...

（文章来源：每日经济新闻） 9月5日，康辰药业公告，公司控股股东刘建华先生计划在2025年9月29日至2025年12月28日期间，通过 集中竞价和大宗交易方式减持不超过478.07万股，占公司总股本的3%。减持原因是自身资金需求。减 持价格将根据市场情况确定。减持计划的实施存在不确定性，具体取决于市场情况、自身实际情况及监 管部门政策变化等因素。 ...

Core Viewpoint - Kangchen Pharmaceutical announced a share reduction plan by its controlling shareholder Liu Jianhua due to personal funding needs, which may impact the company's stock performance [1] Summary by Relevant Sections - **Share Reduction Plan** - Liu Jianhua plans to reduce his holdings by up to 4.7807 million shares, representing no more than 3% of the company's total share capital [1] - The reduction will occur within three months starting from 15 trading days after the announcement [1] - **Method of Reduction** - The share reduction will be executed through both centralized bidding and block trading methods [1] - Up to 1.5936 million shares will be sold via centralized bidding, while up to 3.1871 million shares will be sold through block trading [1] - **Pricing and Uncertainty** - The selling price will be determined based on the market price at the time of the reduction [1] - The implementation of this reduction plan carries uncertainty [1]

Group 1 - The core point of the article is that Kangchen Pharmaceutical's innovative drug KC1036 has been included in the "Children's Antitumor Drug Research and Development Encouragement Pilot Program (Starlight Program)" by the National Medical Products Administration [1] - The company will actively report progress or results related to the implementation framework required by the drug review center to jointly promote the clinical development and market launch of KC1036 in the field of pediatric Ewing's sarcoma [1] - Additionally, the company's controlling shareholder, Liu Jianhua, plans to reduce his holdings by a total of no more than 4.7807 million shares, which is not more than 3% of the company's total shares, through centralized bidding and block trading [1]

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-051 北京康辰药业股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、减持主体的基本情况 1 | | 其他：/ | | --- | --- | | 持股数量 | 50,786,760股 | | 持股比例 | 31.87% | | 当前持股股份来源 | IPO 前取得：50,786,760股 | 上述减持主体存在一致行动人： 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，北京康辰药业股份有限公司（以下简称"公司"）控 股股东刘建华先生持有公司股份 50,786,760 股，占公司总股本的 31.87%（以公 司截至 2025 年 9 月 5 日总股本即 159,356,477 股为基数计算，下同）。 减持计划的主要内容 自本公告披露之日起 15 个交易日后的 3 个月内（根据法律法规禁止减持的 期间除外），刘建华先生因自身资金需求拟通过集中竞价、大宗交易方式减持其 所持有的公司股份，合计不超过 4,78 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-052 由药审中心组织制定的"儿童抗肿瘤药物研发鼓励试点计划（星光计划）"， 主要为贯彻落实国家药监局"提前介入、一企一策、全程指导、研审联动"的要求， 加强与申请人的沟通交流，就抗肿瘤药物儿童人群研究过程中技术难点提供针对性 指导，提高儿童抗肿瘤药物的研发效率。 本次公司 KC1036 作为首批首个入选"星光计划"的创新药品种，代表药审中 心对 KC1036 创新性和在青少年尤文肉瘤患者获益性上的认可，更推动公司关注中 北京康辰药业股份有限公司 关于 KC1036 纳入药审中心"星光计划"试点项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）1 类创新药 KC1036 被国家药品监督管理局药品审评中心（以下简称"药审中心"）纳入"儿童抗肿瘤 药物研发鼓励试点计划（星光计划）"。现将主要情况公告如下： 一、药品相关情况 KC1036 是公司自主研发的化学药品 1 类创新药，公司拥有该产品的全球知识 产 ...

Core Viewpoint - Kangchen Pharmaceutical's innovative drug KC1036 has been included in the "Children's Antitumor Drug Development Encouragement Pilot Program (Star Program)" by the National Medical Products Administration's Drug Evaluation Center, highlighting its potential in pediatric oncology [1] Group 1: Product Development - KC1036 is a class 1 innovative chemical drug developed independently by the company, with global intellectual property rights [1] - The drug exhibits antitumor activity by inhibiting multiple targets such as VEGFR2 and AXL [1] - Over 300 adult cancer patients have participated in clinical studies for KC1036, showing significant antitumor activity and good safety and tolerability across various indications, including gastrointestinal and thymic tumors [1] Group 2: Regulatory Recognition - KC1036 is the first innovative drug to be included in the "Star Program," indicating recognition from the Drug Evaluation Center regarding its innovation and potential benefits for pediatric patients with Ewing's sarcoma [1] - The company plans to actively report progress and results related to the implementation framework required by the Drug Evaluation Center to advance clinical research and market entry for KC1036 in the pediatric Ewing's sarcoma field [1]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company has shown a steady recovery in performance, with a 13.8% year-on-year increase in revenue to 461 million yuan in the first half of 2025, and a 15% increase in net profit to 90 million yuan [1] - The marketing reform has yielded positive results, with significant growth in self-operated regions and a reduction in sales expense ratio to 44.35%, down 3.49 percentage points year-on-year [1] - The innovative drug pipeline is progressing well, with multiple products in various stages of clinical trials, indicating a promising future for the company [2][3] Financial Performance - For the first half of 2025, the company achieved a revenue of 461 million yuan, with a net profit of 90 million yuan, and a non-GAAP net profit of 96 million yuan, reflecting year-on-year growth rates of 13.8%, 15%, and 29.2% respectively [1] - The company expects net profits to reach 152 million yuan, 183 million yuan, and 220 million yuan for the years 2025, 2026, and 2027, with corresponding growth rates of 259.8%, 20.3%, and 20.1% [3][4] - The projected P/E ratios for 2025, 2026, and 2027 are 59X, 49X, and 41X respectively, indicating a favorable valuation outlook [3][4] Product Development - The company is advancing its innovative drug products, including KC1086, which is in Phase I clinical trials for treating advanced solid tumors, and KC1036, which is in Phase III trials with expected progress [2] - The submission of ZY5301 for Pre-NDA has been accepted, targeting chronic pelvic pain, and the registration application for a veterinary product has also been accepted [2] Strategic Investments - The company has invested 150 million yuan in a financing round for a subsidiary, enhancing its portfolio in respiratory innovation and commercial products [3]

Market Trends - The domestic market indices showed a decline, with the Shanghai Composite Index closing at 3,765.88, down 1.25%, and the Shenzhen Component Index down 2.83% [4] - The overall market saw a significant increase in trading volume, with A-share transaction amounts reaching 14.92 trillion yuan, a 15.29% increase week-on-week [7] Industry Commentary - The non-bank financial sector reported a substantial increase in brokerage performance, with 42 listed brokerages achieving a total revenue of 251.87 billion yuan, a year-on-year increase of 11.37%, and a net profit of 104.02 billion yuan, up 65.08% [6][7] - The communication sector is experiencing a surge in demand, particularly driven by Alibaba Cloud's Q2 performance, which exceeded expectations with a revenue increase of 26% to 33.4 billion yuan [8] Company Insights - Huafeng Technology (688629.SH) reported a significant revenue increase of 128.26% year-on-year, reaching 1.105 billion yuan in H1 2025, with a net profit of 151 million yuan, up 940.64% [10] - China General Nuclear Power Corporation (01164.HK) faced a revenue decline of 58% to 1.709 billion HKD in H1 2025, primarily due to accounting standards affecting trade business [12] - Kangchen Pharmaceutical (603590.SH) achieved a revenue of 460 million yuan in H1 2025, reflecting a growth of 13.8% [14] - Longjiang Securities (000783.SZ) reported a significant recovery in investment business, with a notable increase in operating performance [28] Investment Recommendations - The report suggests a "Buy-B" rating for Huafeng Technology, anticipating continued growth in the domestic AI server market and communication modules [10][11] - For China General Nuclear Power, a "Buy-B" rating is maintained, with expectations of recovery in profitability driven by strategic contracts and market demand [13] - Kangchen Pharmaceutical is also rated "Buy-B," with projected revenue growth driven by innovative drug development [14] Future Projections - Huafeng Technology is expected to continue benefiting from the domestic AI server market, with projections indicating a strong performance in the coming years [10][11] - China General Nuclear Power anticipates a rebound in net profit, with estimates of 3.76 billion HKD in 2025, growing significantly in subsequent years [13] - Kangchen Pharmaceutical forecasts revenues of 9.41 billion yuan by 2027, indicating robust growth potential [14]